12:00 AM
 | 
Sep 20, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Arzerra ofatumumab: Phase II data

In a double-blind, dose-escalation, crossover Phase II trial in 26 patients initially treated with IV ofatumumab for 24 weeks and then crossed over to placebo, repeated MRI scans showed a sustained reduction in the number of brain lesions up to week 48. Additionally, the 12 subjects who received placebo for the first 24 weeks and then crossed over to treatment with IV ofatumumab had similar results as those initially treated...

Read the full 327 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >